Paper39736693
Disrupting USP39 deubiquitinase function impairs the survival and migration of multiple myeloma cells through ZEB1 degradation.
Sirera J and 14 others. J Exp Clin Cancer Res, 2024. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Disrupting USP39 deubiquitinase function impairs the survival and migration of multiple myeloma cells through ZEB1 degradation. Papers, record 39736693. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39736693
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Disrupting USP39 deubiquitinase function impairs the survival and migration of multiple myeloma cells through ZEB1 degradation.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Zinc Finger E-box-Binding Homeobox 1 | Major topic |
| Cell Movement | Major topic |
| Ubiquitin-Specific Proteases | Major topic |
| Humans | |
| Animals | |
| Zebrafish | |
| Cell Line, Tumor | |
| Deubiquitinating Enzymes | |
| Cell Survival | |
| Mice |
Source PubMed
References55
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34197957 | USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma. | Cell Signal | 2021 | https://conductscience.org/library/papers/34197957 | PubMed |
| 2 | 31723771 | ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes? | Hemasphere | 2018 | https://conductscience.org/library/papers/31723771 | PubMed |
| 3 | 28154181 | USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. | J Biol Chem | 2017 | https://conductscience.org/library/papers/28154181 | PubMed |
| 4 | 26513019 | UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression. | Oncotarget | 2015 | https://conductscience.org/library/papers/26513019 | PubMed |
| 5 | 37212518 | Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis. | Cancer Med | 2023 | https://conductscience.org/library/papers/37212518 | PubMed |
| 6 | 33127822 | USP39 Serves as a Deubiquitinase to Stabilize STAT1 and Sustains Type I IFN-Induced Antiviral Immunity. | J Immunol | 2020 | https://conductscience.org/library/papers/33127822 | PubMed |
| 7 | 36940483 | USP10 Regulates ZEB1 Ubiquitination and Protein Stability to Inhibit ZEB1-Mediated Colorectal Cancer Metastasis. | Mol Cancer Res | 2023 | https://conductscience.org/library/papers/36940483 | PubMed |
| 8 | 24126978 | Lentivirus-mediated inhibition of USP39 suppresses the growth of breast cancer cells in vitro. | Oncol Rep | 2013 | https://conductscience.org/library/papers/24126978 | PubMed |
| 9 | 29556295 | Downregulation of ubiquitin-specific peptidase 39 suppresses the proliferation and induces the apoptosis of human colorectal cancer cells. | Oncol Lett | 2018 | https://conductscience.org/library/papers/29556295 | PubMed |
| 10 | 12826635 | A phase 2 study of bortezomib in relapsed, refractory myeloma. | N Engl J Med | 2003 | https://conductscience.org/library/papers/12826635 | PubMed |
| 11 | 27344946 | MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome. | Cancer Cell | 2016 | https://conductscience.org/library/papers/27344946 | PubMed |
| 12 | 32549302 | Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32549302 | PubMed |
| 13 | 25051369 | The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. | Oncotarget | 2014 | https://conductscience.org/library/papers/25051369 | PubMed |
| 14 | 22535658 | Myeloma as a model for the process of metastasis: implications for therapy. | Blood | 2012 | https://conductscience.org/library/papers/22535658 | PubMed |
| 15 | 15958804 | Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. | N Engl J Med | 2005 | https://conductscience.org/library/papers/15958804 | PubMed |
| 16 | 20023629 | Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. | Nature | 2010 | https://conductscience.org/library/papers/20023629 | PubMed |
| 17 | 36119839 | USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1. | Am J Cancer Res | 2022 | https://conductscience.org/library/papers/36119839 | PubMed |
| 18 | 30771428 | USP39 regulates DNA damage response and chemo-radiation resistance by deubiquitinating and stabilizing CHK2. | Cancer Lett | 2019 | https://conductscience.org/library/papers/30771428 | PubMed |
| 19 | 35203300 | Epithelial Mesenchymal Transition (EMT) and Associated Invasive Adhesions in Solid and Haematological Tumours. | Cells | 2022 | https://conductscience.org/library/papers/35203300 | PubMed |
| 20 | 15650264 | Targeting multiple myeloma cells and their bone marrow microenvironment. | Ann N Y Acad Sci | 2004 | https://conductscience.org/library/papers/15650264 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42274330 | MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer. | Mol Cancer Res | 2026 | https://conductscience.org/library/papers/42274330 | PubMed |
| 41596492 | RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41596492 | PubMed |
| 41208892 | Role of Ubiquitin-regulated EMT in Cancer Metastasis and Chemoresistance. | Int J Biol Sci | 2025 | https://conductscience.org/library/papers/41208892 | PubMed |
| 40734978 | Post-translational modifications orchestrate mTOR-driven cell death in cardiovascular disease. | Front Cardiovasc Med | 2025 | https://conductscience.org/library/papers/40734978 | PubMed |
| 40295433 | Serine metabolism in tumor progression and immunotherapy. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40295433 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD38 | 952 | PubTator's text mining | https://conductscience.org/library/genes/952 | NCBI Gene |
| USP39 | 10713 | PubTator's text mining | https://conductscience.org/library/genes/10713 | NCBI Gene |
| ZEB1 | 6935 | PubTator's text mining | https://conductscience.org/library/genes/6935 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39736693
GET https://conductscience.org/api/papers/v1/39736693/references?page=2